Courey seemed quite concerned about the Generic business when they were trying to acquire King a while back I thought they may seek to diversify outside or perhaps get into Bio-generics.
Dew from your posts you seem to follow the generic business quite a bit. Thoughts on Courey aside are you familiar with the Merck KG Generic business, do you think it is a good deal for MYL or just "empire building" at the expense of diluting shareholders? TIA
Market Data 
Markets 
AI
